Serum Hepatocyte Growth Factor Is Probably Associated With 3-Month Prognosis of Acute Ischemic Stroke

Zhu, Zhengbao; Xu, Tan; Guo, Daoxia; Huangfu, Xinfeng; Zhong, Chongke; Yang, Jingyuan; Wang, Aili; Chen, Chung-Shiuan; Peng, Yi; Xu, Tian; Wang, Jinchao; Sun, Yingxian; Peng, Hao; Li, Qunwei; Ju, Zhong; Geng, Deqin; Chen, Jing; Zhang, Yonghong; He, Jiang

doi:10.1161/strokeaha.117.019476

Cited by 28 publications

(21 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results may seem to contradict the biological functions of IL-37, such as anti-inflammation, immune regulation and a reduction in atherosclerosis. Nevertheless, these results were very similar to those previously reported for natriuretic peptide 43 and hepatic growth factor (HGF), 44 which are both known to be protective in AIS patients, even though elevated levels are strong predictors of poor outcomes. The underlying mechanisms linking the increased IL-37 level at admission and an unfavourable functional outcome have not been clearly demonstrated.…”

Section: Discussionsupporting

confidence: 89%

<p>Plasma Interleukin-37 is Elevated in Acute Ischemic Stroke Patients and Probably Associated With 3-month Functional Prognosis </p>

Zhang¹,

Zhu²,

Li³

et al. 2020

CIA

View full text Add to dashboard Cite

Background: Interleukin-37 is a novel cytokine emerging as a natural suppressor of inflammatory responses. Inflammation and the immune response play important roles in acute ischemic stroke. This study aimed at evaluating the plasma levels and the association with 3-month outcomes of interleukin-37 in acute ischemic stroke patients. Patients and Methods: In total, 152 consecutive patients with acute ischemic stroke and 45 healthy controls were included. Plasma interleukin-37 levels were determined in the first morning after admission using an enzyme-linked immunesorbent assay. The primary outcome was the 3-month functional outcome (modified Rankin Scale score >2). Logistic regression was used to evaluate the risk and 3-month outcome of stroke according to plasma interleukin-37 level. Results: Plasma interleukin-37 levels were significantly higher in the patients with acute ischaemic stroke than in the healthy controls (182.26 versus 97.89 pg/mL, p<0.001). Patients with large-artery atherosclerosis had significantly higher IL-37 levels than those with smallartery occlusion (202.12±35.82 versus 175.67±33.71pg/mL, p<0.001). Plasma interleukin-37 levels were positively correlated with National Institutes of Health Stroke Scale scores (r=0.521, p<0.0001) and lesion volume (r=0.442, p<0.0001). Ninety-four and 58 patients had favourable and unfavourable 3-month outcomes, respectively. Elevated plasma interleukin-37 levels were independently associated with unfavourable 3-month outcomes (adjusted odds ratio=1.033, p=0.001, 95% confidence interval: 1.015-1.056). Conclusion: Admission plasma interleukin-37 levels were significantly increased after acute ischemic stroke. Elevated interleukin-37 levels were independently associated with unfavourable 3-month prognoses in acute ischemic stroke patients. Further studies with other populations are needed.

show abstract

Section: Discussionsupporting

confidence: 89%

<p>Plasma Interleukin-37 is Elevated in Acute Ischemic Stroke Patients and Probably Associated With 3-month Functional Prognosis </p>

Zhang¹,

Zhu²,

Li³

et al. 2020

CIA

View full text Add to dashboard Cite

show abstract

“…Upon further examination in a larger sample size, we found that seven cytokines including HGF, IL-1β, IL-2, sIL-2R, IL-5, IL-10, and MIP-3α were definitely upregulated in 204 AIS patients compared to 76 healthy controls and had diagnostic value. Since HGF, IL-1β, IL-2, IL-5, and IL-10 have been reported previously [17][18][19], our findings confirmed and extended prior studies on the relations between various biomarkers and diagnosis after AIS. Our first contribution was to identify two totally new biomarkers sIL-2R and MIP-3α for AIS patients, which can provide references to other studies and help target particular pathways to prevent the progression of ischemic stroke.…”

Section: Discussionsupporting

confidence: 91%

“…Zhu et al reported that HGF was associated with mortality but not disability at 3 months after ischemic stroke onset [18]. However, they included patients within 48 hours of symptom onset and excluded patients treated with rt-PA [18]. By comparison, patients' blood in our study was collected within 24 hours before they received any treatment.…”

Section: Discussionmentioning

confidence: 94%

“…Clinically, HGF is a biomarker of atherosclerotic disease [23] and positively associated with the incidence of stroke [24,25]. Zhu et al reported that HGF was associated with mortality but not disability at 3 months after ischemic stroke onset [18]. However, they included patients within 48 hours of symptom onset and excluded patients treated with rt-PA [18].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The incremental prognostic value of sIL-2R and HGF in acute ischemic stroke

Zhao

Huang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Inflammation affect long-term neurological outcome after acute ischemic stroke (AIS). Comprehensive and insightful understanding of correlation of inflammatory mediators and stroke outcome may offer new biomarkers or therapeutic approaches for AIS. Methods: We collected plasma from 204 AIS patients and 76 healthy controls, and ten cytokines (HGF, IL-1β, IL-2, sIL-2R, IL-5, IL-10, IL-16, MIP-3α, CD40L and MMP1) screened out by Immune Monitoring 65-Plex Human ProcartaPlex Panel were measured. Functional outcome 3 months after stroke was assessed using the modified Rankin Scale. To assess the prognostic ability of inflammatory mediators, we applied multivariate logistic regression and construction of multimarker score. Results: HGF, IL-10, IL-1β, MIP-3α, IL-2, sIL-2R, and IL-5 were significantly upregulated in AIS patients compared to controls. After multivariable adjustment, sIL-2R (OR, 1.138; 95% CI, 1.028-1.259; P=0.012) and HGF (OR, 1.121; 95% CI, 1.030-1.218; P=0.008) remained individually associated with unfavorable outcomes at 3 months after AIS (p < 0.05). Furthermore, adding sIL-2R and HGF to the conventional model significantly improved risk reclassification for unfavorable outcomes (continuous net reclassification improvement 32.18%, p < 0.001; integrated discrimination improvement 10.21%, p < 0.001). Conclusions: Higher plasma sIL-2R was a new independent predictor of unfavorable outcomes in AIS, and incorporation of sIL-2R and HGF into the conventional model significantly improved risk stratification for unfavorable outcomes.

show abstract

“…Moreover, Susen et al [20] found that high serum HGF is an independent predictor of a composite of death and myocardial infarction. In terms of stroke, HGF was proved to be positively associated with the incidence of stroke [21,22], and Zhu et al [23] reported that higher HGF was associated with mortality but not disability at 3 months after ischemic stroke onset. However, Zhu et al included patients within 48 hours of symptom onset and excluded patients treated with rt-PA. By comparison, patients' blood in our study was collected within 24 hours before they received any treatment.…”

Section: Discussionmentioning

confidence: 99%

The incremental prognostic value of sIL-2R and HGF in acute ischemic stroke

Zhao

Huang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Inflammation affect long-term neurological outcome after acute ischemic stroke (AIS). Comprehensive and insightful understanding of correlation of inflammatory mediators and stroke outcome may offer new biomarkers or therapeutic approaches for AIS.Methods: We collected plasma from in 204 AIS patients and 76 healthy controls, and ten cytokines (HGF, IL-1β, IL-2, sIL-2R, IL-5, IL-10, IL-16, MIP-3α, CD40L and MMP1) screened out by Immune Monitoring 65-Plex Human ProcartaPlex Panel were measured. Functional outcome 3 months after stroke was assessed using the modified Rankin Scale. To assess the prognostic ability of inflammatory mediators, we applied multivariate logistic regression and construction of multimarker score.Results: HGF, IL-10, IL-1β, MIP-3α, IL-2, sIL-2R, and IL-5 were significantly upregulated in AIS patients compared to control. After multivariable adjustment, sIL-2R (OR, 1.138; 95% CI, 1.028-1.259; P=0.012) and HGF (OR, 1.121; 95% CI, 1.030-1.218; P=0.008) remained individually associated with unfavorable outcomes at 3 months (p < 0.05). Furthermore, adding sIL-2R and HGF to the conventional model significantly improved risk reclassification for unfavorable outcomes (continuous net reclassification improvement 32.18%, p < 0.001; integrated discrimination improvement 10.21%, p < 0.001).Conclusions: Higher plasma sIL-2R was a new independent predictor of unfavorable outcomes in AIS, and incorporation of sIL-2R and HGF into the conventional model significantly improved risk stratification for unfavorable outcomes.

show abstract

Serum Hepatocyte Growth Factor Is Probably Associated With 3-Month Prognosis of Acute Ischemic Stroke

Cited by 28 publications

References 38 publications

<p>Plasma Interleukin-37 is Elevated in Acute Ischemic Stroke Patients and Probably Associated With 3-month Functional Prognosis </p>

<p>Plasma Interleukin-37 is Elevated in Acute Ischemic Stroke Patients and Probably Associated With 3-month Functional Prognosis </p>

The incremental prognostic value of sIL-2R and HGF in acute ischemic stroke

The incremental prognostic value of sIL-2R and HGF in acute ischemic stroke

Contact Info

Product

Resources

About